PMHNP Scope of Practice for ADHD

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth for ADHD care, you’ve probably hit this question: Can I legally prescribe stimulants like Adderall through a video visit?

The short answer in 2026: Yes — but with important caveats that depend on federal extensions, pending DEA rules, and your state’s scope of practice laws.

Let’s cut through the regulatory confusion. This guide walks through what’s currently allowed, what’s changing, and how it affects your ability to build a sustainable ADHD telehealth practice.

The Federal Landscape: Where We Are Right Now

The Ryan Haight Act and COVID Waivers

Under normal circumstances, the Ryan Haight Act requires an in-person medical evaluation before prescribing any controlled substance via telemedicine. For ADHD providers, this meant you couldn’t legally prescribe Adderall, Ritalin, or other Schedule II stimulants after just a video consultation.

COVID changed everything. In March 2020, the DEA waived that in-person requirement, allowing providers to prescribe Schedule II–V controlled substances via telehealth as long as the encounter met standard-of-care requirements and used real-time audiovisual communication.

Current Status (Through December 31, 2026): The DEA and HHS have extended these telehealth flexibilities for the fourth time, now running through the end of 2026. This means you can continue prescribing ADHD medications via video visits without any initial in-person exam, as long as you’re following proper prescribing protocols — legitimate diagnosis, thorough evaluation, documented treatment plan, and compliance with state PDMP requirements.

What’s Coming: Permanent DEA Rules

The DEA has been working on permanent telemedicine regulations to replace these temporary extensions. In January 2025, they previewed three new rules that will likely take effect in 2027:

1. Telemedicine Special Registration
The DEA plans to create a special registration pathway for providers who want to prescribe controlled substances via telehealth without in-person exams. Key requirements will include:

• Mandatory nationwide PDMP checks
• Strict patient identity verification during audiovisual consults
• Compliance with additional safeguards (exact details still pending final rule publication)

2. Established Patient Exception
If you’ve seen a patient in person at least once (or another provider in your practice has), telehealth prescribing of controlled substances won’t face additional restrictions. This is crucial for hybrid practices or providers transitioning existing patients to virtual care.

3. Platform Registration
Telehealth companies that facilitate virtual visits will need to register with the DEA, adding corporate-level oversight to prevent abuse.

Bottom line: Prepare to obtain the special telemedicine registration when it becomes available. It’ll be your ticket to continue ADHD telehealth prescribing without interruption after 2026.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: The Details That Matter

Federal law sets the baseline, but state regulations determine your actual scope of practice. Here’s what you need to know for our six priority states.

California: Progressive but License-Heavy

Telehealth Prescribing: California explicitly allows prescribing via telehealth if the evaluation meets standard of care — even asynchronous methods can satisfy the exam requirement. No state-imposed in-person visit mandate.

NP Scope: California is transitioning to Full Practice Authority for nurse practitioners. By 2026, experienced NPs (3+ years or 4,600 hours under physician supervision) can practice and prescribe independently, including ADHD medications. New graduates still need supervising physicians initially.

Key Requirement: You must check California’s CURES PDMP database before the initial prescription and at least every 4 months for ongoing Schedule II therapy.

Licensure Reality: No shortcuts — you need a full California license. CA isn’t part of the Interstate Medical Licensure Compact, and there’s no special telehealth registration for out-of-state providers.

Texas: Physician-Only for Stimulants

Telehealth Prescribing: Texas allows telemedicine for mental health treatment, and physicians can prescribe ADHD medications via video visits. No special state prohibition beyond federal requirements.

The NP Problem: Here’s where Texas gets restrictive. Nurse practitioners and physician assistants cannot prescribe Schedule II controlled substances to outpatients. Period. The only exceptions are hospital inpatient orders (≥24 hours), hospice care, or ER medication orders.

What this means: If you’re an NP or PA practicing in Texas, you cannot write prescriptions for Adderall, Ritalin, or other stimulants for ADHD patients, even with physician supervision. Only MD/DO psychiatrists can prescribe these medications in outpatient settings.

For Platforms: Texas requires physician coverage for all ADHD medication prescribing. NPs can evaluate and manage patients, but a physician must handle the actual prescriptions.

PDMP: Texas mandates checking the Prescription Monitoring Program for opioids and benzodiazepines, but not technically for stimulants. Still, checking it for any controlled substance is best practice and may protect you in case of audit.

Florida: Clear Psychiatric Exception

Telehealth Prescribing: Florida law explicitly permits prescribing Schedule II controlled substances via telehealth for treatment of psychiatric disorders — which includes ADHD. This carve-out makes Florida one of the most telehealth-friendly states for mental health prescribing.

Out-of-State Option: Florida offers an out-of-state telehealth provider registration. If you’re licensed in another state, you can register with Florida’s Department of Health to provide telehealth services to Florida patients without obtaining a full Florida license. The psychiatric exception still applies, so you can prescribe ADHD medications remotely.

NP Scope: Psychiatric nurse practitioners in Florida can prescribe stimulants without the standard 7-day Schedule II limit that applies to other APRNs. However, PMHNPs must work under a protocol agreement with a supervising psychiatrist (Florida hasn’t granted independence to psychiatric NPs like it has for some primary care NPs).

PDMP Requirement: Florida’s E-FORCSE system must be checked before prescribing controlled substances to patients 16 and older. Document every check.

New York: Aligned with Federal Rules

Telehealth Prescribing: As of May 2025, New York updated its regulations to explicitly permit prescribing controlled substances via telehealth consistent with federal law. Translation: as long as the DEA allows it, New York allows it.

NP Independence: New York is relatively progressive. Psychiatric NPs with more than 3,600 hours of practice experience can practice independently without a written collaborative agreement, including prescribing Schedule II stimulants.

Practical Advantage: New York allows up to 90-day prescriptions for ADHD medications (versus the typical 30-day limit) if you indicate the prescription is for ADHD using the appropriate diagnostic code. This is a huge time-saver for stable patients in ongoing telehealth care.

PDMP Mandate: New York’s I-STOP law requires checking the PMP registry for every Schedule II–IV prescription. This is strictly enforced. E-prescribing is also mandatory for all controlled substances (no paper prescriptions allowed).

Licensure: You need a full New York license — the state isn’t part of the Interstate Medical Licensure Compact and doesn’t offer a special telehealth registration.

Pennsylvania: 30-Day Limit for NPs

Telehealth Prescribing: Pennsylvania doesn’t impose state-level restrictions beyond federal law. Telemedicine is acceptable for ADHD treatment as long as the evaluation meets standard of care.

NP Restrictions: Pennsylvania requires nurse practitioners to work under a collaborative agreement with a physician. More importantly, CRNPs are limited to 30-day supplies of Schedule II controlled substances. Any continuation beyond 30 days requires physician approval — not necessarily an in-person physician visit with the patient, but the supervising physician must review and OK continued therapy.

PDMP: Required to check Pennsylvania’s PDMP before the initial prescription in any new course of treatment. Many providers check it for every stimulant prescription to be safe.

E-Prescribing: Mandatory for controlled substances (with very few exceptions) since 2019.

Licensure: Pennsylvania is part of the Interstate Medical Licensure Compact, making it easier for out-of-state physicians to obtain a PA license for telehealth practice.

Illinois: Two-Tier NP System

Telehealth Prescribing: Illinois fully permits telemedicine for mental health and follows federal controlled substance rules. No state-imposed in-person exam requirement.

NP Scope — Two Pathways:

Under Collaboration: NPs working with a collaborative physician agreement can prescribe Schedule II controlled substances for up to 30 days, but any continuation requires physician approval. The collaborating physician must also conduct monthly reviews of the NP’s Schedule II prescribing.

Full Practice Authority: Illinois allows APRNs who complete 4,000 hours of collaborative practice plus 250 hours of additional training to apply for Full Practice Authority status. FPA-certified NPs can prescribe independently — and here’s the key: the special consultation requirement for Schedule II ‘narcotic drugs’ (opioids) and benzodiazepines does not apply to stimulants. Stimulants are Schedule II non-narcotic controlled substances, so an FPA PMHNP in Illinois can prescribe Adderall without any physician oversight.

The Big Picture: If you’re an NP in Illinois without FPA, you need physician backup and face the 30-day limit. If you have FPA, you’re fully autonomous for ADHD prescribing.

Interesting Note: Illinois allows ‘Prescribing Psychologists’ with special training to prescribe some psychotropic medications, but they’re explicitly barred from prescribing Schedule II substances. So ADHD medication management remains with physicians and nurse practitioners.

State Comparison: Quick Reference

The Economics: Why Telehealth ADHD Makes Business Sense

Let’s talk about the practical side: building a sustainable ADHD practice.

Traditional Marketing Reality:
If you’re trying to build an ADHD patient panel through DIY marketing, you’re looking at:

• $200–500+ per acquired patient when you factor in all costs — SEO agency fees, Google Ads spend, directory listings, staff time qualifying leads, and the inevitable no-shows from cold marketing
• 6–12 months before SEO generates meaningful patient flow
• $15–40+ per click for mental health keywords on Google Ads, with most clicks not converting to booked patients
• Monthly directory fees (Psychology Today, Zocdoc) where you compete with hundreds of other providers on the same page
• $3,000–5,000/month in marketing spend with uncertain ROI

The Platform Alternative:
Platforms like Klarity Health use a pay-per-appointment model. Instead of gambling thousands on marketing channels that might not work, you pay a standard listing fee only when a qualified patient books with you.

Why this matters:

• No upfront marketing spend or monthly subscriptions eating into revenue
• Pre-qualified patients already matched to your specialty, availability, and insurance/cash-pay preference
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Guaranteed ROI — you only pay when you actually see patients

For providers starting out or scaling up, this removes the biggest risk: spending months and thousands of dollars building a patient pipeline that may never materialize. You get immediate access to patient flow and can focus on what you do best — clinical care.

Compliance Essentials: Protecting Your License

Regardless of which state you practice in, these are non-negotiable:

1. Proper Clinical Evaluation
A quick questionnaire isn’t enough. Your telehealth visit must include a thorough diagnostic interview covering DSM-5 ADHD criteria, functional impairment assessment, symptom history, and ruling out other conditions. Document everything as if you were seeing the patient in person.

2. State PDMP Checks
Most states require checking the Prescription Drug Monitoring Program before prescribing controlled substances. Even if your state doesn’t explicitly mandate it for stimulants, check it anyway. It protects you and your patient.

3. Electronic Prescribing
E-prescribing is mandatory for controlled substances in most states (California, Texas, Florida, New York, Pennsylvania, Illinois all require it). Make sure your EHR system supports EPCS (Electronic Prescribing of Controlled Substances).

4. Appropriate Standard of Care
The DEA and state medical boards expect the same standard of care via telehealth as in person. That means:

• Real-time audiovisual communication (not just phone or messaging)
• Proper identity verification
• Documented treatment plan with dosing rationale
• Appropriate follow-up intervals
• Clear emergency protocols

5. Stay Current on DEA Rules
The regulatory landscape is shifting. When the DEA finalizes permanent telemedicine rules (likely in 2027), you’ll need to:

• Obtain the telemedicine special registration if you haven’t established an in-person relationship with patients
• Comply with new PDMP and identity verification requirements
• Possibly register with a national PDMP data hub

Common Questions Providers Ask

Do I need to see ADHD patients in person eventually?
Not under current federal rules (through 2026). Some states may have additional requirements, but none of our priority states mandate periodic in-person visits for ongoing ADHD treatment established via telehealth. Once permanent DEA rules take effect, the ‘established patient’ exception will likely mean if you see a patient in person once, you can continue care indefinitely via telehealth.

Can I prescribe 90-day supplies of stimulants via telehealth?
Depends on the state. New York explicitly allows 90-day ADHD prescriptions with appropriate coding. Most other states follow a 30-day standard for Schedule II controlled substances. Some states (like Pennsylvania and Illinois for non-FPA NPs) require physician consultation before any refill beyond 30 days.

What about treating pediatric ADHD patients via telehealth?
Clinically appropriate and legally allowed, with caveats:

• Parent/guardian consent is required (as it would be for any minor’s treatment)
• Some states may require the parent/guardian to be present during the telehealth visit
• In Florida, PMHNPs treating minors with controlled substances must have a consulting pediatrician or psychiatrist involved
• Document parent/guardian participation and consent clearly

Do audio-only visits qualify?
No. For prescribing controlled substances via telehealth, the DEA requires real-time audiovisual communication. Phone-only consultations don’t meet the standard (with very limited exceptions for buprenorphine in substance use disorder treatment, which doesn’t apply to ADHD).

What if I’m licensed in multiple states?
You can practice telehealth in any state where you hold an active license, following that state’s specific rules. Multi-state licensure is becoming more common for telehealth providers, especially through the Interstate Medical Licensure Compact (for physicians) and some state-specific telehealth registrations like Florida’s.

Making the Move to Telehealth ADHD Care

The regulatory environment for ADHD telehealth is actually more stable than it appears. Yes, there are federal rules in flux and state-by-state variations, but the fundamentals are clear:

For Psychiatrists: You have full prescriptive authority in all 50 states. As long as you’re licensed in the patient’s state, comply with PDMP requirements, and follow standard prescribing protocols, you can build a thriving telehealth ADHD practice. The biggest hurdle is often just getting licensed in additional states if you want to expand your reach.

For Psychiatric NPs: Your ability to prescribe ADHD medications independently depends heavily on your state. California, New York, and Illinois (with FPA) offer the most autonomy. Texas requires physician backup for the actual prescribing. Florida, Pennsylvania, and Illinois (without FPA) fall in between, requiring collaborative agreements with varying degrees of physician involvement.

For Both: The patient demand is enormous. ADHD is one of the most common psychiatric conditions, and there’s a severe shortage of providers — especially in rural areas and underserved communities. Telehealth removes geographic barriers and gives you access to patients who desperately need care but can’t access it locally.

The Path Forward

Here’s what to do if you’re ready to start treating ADHD patients via telehealth:

1. Verify Your State Requirements
Review your state’s specific rules on PDMP checks, e-prescribing mandates, and scope of practice limitations. If you’re an NP, understand whether you need a collaborative agreement and what that entails for controlled substance prescribing.

2. Get Your Systems in Place

• Set up EPCS capability in your EHR
• Register with your state’s PDMP (and any states where you’ll practice)
• Ensure your telehealth platform meets audiovisual requirements
• Create templated documentation that captures all required clinical elements

3. Understand the Economics
Whether you build your own practice through marketing or join a platform, know your numbers. How many patients do you need to see monthly to hit your income goals? What’s your time worth? What does patient acquisition actually cost?

For many providers, especially those starting out or adding telehealth to an existing practice, a platform model offers the fastest path to sustainable patient volume without the marketing risk.

4. Stay Informed
The DEA will finalize permanent telemedicine rules sometime in 2026-2027. When they do, you’ll likely need to take action — obtaining special registration, updating compliance protocols, or adjusting your practice model. Subscribe to DEA updates and follow professional organizations that track these changes.

5. Focus on Quality
The DEA has investigated some telehealth companies for alleged over-prescription of stimulants. Protect yourself and your patients by maintaining high clinical standards:

• Thorough diagnostic evaluations
• Regular follow-up and monitoring
• Documented rationale for medication choices and dosing
• Willingness to adjust treatment or refer when appropriate
• Clear boundaries and abuse-prevention protocols

Final Thoughts

ADHD telehealth isn’t just legally viable — it’s becoming the standard of care for many patients. The regulatory framework, while complex, is actually designed to balance access with safety. You can prescribe Adderall via video visit. You can build a sustainable practice. You can help thousands of patients who lack local access to psychiatric care.

The key is understanding the rules that apply to your specific situation — your license type, your state, your practice model — and building systems that ensure compliance while delivering excellent care.

If you’re ready to explore telehealth ADHD practice and want access to qualified patients without the marketing headache, Klarity Health offers a straightforward path. Licensed psychiatrists and psychiatric nurse practitioners join our network, treat patients in states where they’re licensed, and get paid per appointment with no upfront costs or monthly fees.

Interested in learning more? Explore joining Klarity’s provider network and see how many ADHD patients in your licensed states are waiting for care.

Sources and References

The following sources were consulted to ensure accuracy and provide authoritative regulatory guidance. All information reflects current law as of February 2026.

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026)
   Official announcement of the fourth extension of telehealth controlled substance prescribing flexibilities through December 31, 2026.
   Source: HHS.gov and Healthcare Dive reporting

2. DEA Press Release – Three New Telemedicine Rules (January 16, 2025)
   DEA announcement previewing permanent telemedicine regulations including special registration requirements, PDMP mandates, and platform registration.
   Source: DEA.gov

3. Texas Board of Nursing – APRN Practice FAQ
   Official guidance confirming that APRNs in Texas cannot prescribe Schedule II controlled substances in outpatient settings.
   Source: bon.texas.gov (current as of 2025)

4. Florida Statutes §456.47 (Telehealth law) and §464.012 (APRN prescribing)
   Primary legal text establishing the psychiatric disorder exception for Schedule II prescribing via telehealth and APRN prescriptive authority limitations.
   Source: leg.state.fl.us (2019 telehealth law; 2017 nursing prescribing statute)

5. New York State Department of Health – Bureau of Narcotic Enforcement Guidance (May 2025)
   Official guidance aligning New York’s controlled substance prescribing regulations with federal telehealth rules.
   Source: NYSDOH via ninthdistrict.org

6. Pennsylvania Code – CRNP Prescriptive Authority Regulations
   Administrative code establishing 30-day supply limits for CRNP prescribing of Schedule II controlled substances.
   Source: pacodeandbulletin.gov (current through 2025)

7. Illinois Administrative Code – Nurse Practice Act Rules
   Official regulations detailing NP collaborative practice requirements, Full Practice Authority pathway, and Schedule II prescribing limitations.
   Source: ilga.gov/agencies/JCAR (reflects 2017 law changes, current through 2024)

8. California Business & Professions Code §2242 and CCHP State Telehealth Laws
   Primary statute confirming that telehealth examinations satisfy prescribing requirements in California.
   Source: California Legislative Information and Center for Connected Health Policy (cchpca.org, updated January 2026)

9. RxAgent – NP Prescriptive Authority by State (2026 Guide)
   Comprehensive analysis of state-by-state nurse practitioner scope of practice laws with citations to primary sources.
   Source: rxagent.co (updated December 28, 2025)

All regulatory claims have been verified against official state statutes, medical board publications, and federal agency releases. This content reflects current law as of February 10, 2026.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care